These data were supported by experiments with mouse tumour models using a specific ATR inhibitor where RT-induced PD-L1 upregulation was significantly suppressed, resulting in the attenuation of RT-induced CD8-positive T cell exhaustion and cancer cells sensitised to the cytotoxicity of CD8-positive T cells [50, 51]. The gene discussed is CD8A; the disease is cancer.